Delcath Systems Q2 2023 Earnings Report $13.16 -0.18 (-1.31%) As of 12:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Delcath Systems EPS ResultsActual EPS-$0.58Consensus EPS -$0.67Beat/MissBeat by +$0.09One Year Ago EPSN/ADelcath Systems Revenue ResultsActual Revenue$0.50 millionExpected Revenue$0.73 millionBeat/MissMissed by -$230.00 thousandYoY Revenue GrowthN/ADelcath Systems Announcement DetailsQuarterQ2 2023Date8/9/2023TimeN/AConference Call ResourcesPress ReleaseDCTH Earnings HistoryPowered by Remove Ads Delcath Systems Earnings HeadlinesJim Cramer Blesses Delcath Systems (DCTH): ‘You’re Not Early, But It’s a Win’March 27 at 10:55 AM | msn.comDelcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual ConferenceMarch 24 at 4:25 PM | businesswire.comThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy shareholder value over time. Even as gold prices rise.March 27, 2025 | Golden Portfolio (Ad)Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 14, 2025 | businesswire.comBTIG Reaffirms Their Buy Rating on Delcath Systems (DCTH)March 13, 2025 | markets.businessinsider.comDelcath Systems, Inc. (NASDAQ:DCTH) Q4 2024 Earnings Call TranscriptMarch 10, 2025 | msn.comSee More Delcath Systems Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Delcath Systems? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Delcath Systems and other key companies, straight to your email. Email Address About Delcath SystemsDelcath Systems (NASDAQ:DCTH), an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.View Delcath Systems ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio?Analysts Lift Archer Aviation Stock Despite Earnings Miss Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
